Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Cancer Letters|September 7, 2024
Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancerMaría Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2025
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast CancerChang-Ching A Lin, María Rosario Chica-Parrado, Nisha Unni, et al.
Cancer Letters|March 24, 2025
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterationsYasuaki Uemoto, Chang-Ching A Lin, Bingnan Wang, et al.
Research Square|February 24, 2023
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatmentShuying Liu, Shelly M Xie, Wenbin Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2013
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesAriella B Hanker, Adam D Pfefferle, Justin M Balko, et al.
Breast Cancer Research : BCR|June 6, 2023
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatmentShuying Liu, Shelly M Xie, Wenbin Liu, et al.
Nature Genetics|August 25, 2015
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancerMichalina Janiszewska, Lin Liu, Vanessa Almendro, et al.
Breast Cancer Research : BCR|June 25, 2024
Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse modelsYun Lu, Hailey A Houson, Carlos A Gallegos, et al.
Cancer Research|April 12, 2017
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2<sup>+</sup> Breast CancerAriella B Hanker, Mónica Valeria Estrada, Giampaolo Bianchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2021
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER<sup>+</sup> Breast CancerAlberto Servetto, Rahul Kollipara, Luigi Formisano, et al.
Pageof 4